Claims for Patent: 5,854,290
✉ Email this page to a colleague
Summary for Patent: 5,854,290
| Title: | Use of guanfacine in the treatment of behavioral disorders |
| Abstract: | Disclosed is a method of treating disorders which have prominent symptoms of behavioral disinhibition (e.g., Attention-Deficit Hyperactivity Disorder, Conduct Disorder, Oppositional Defiant Disorder, Tourette's Syndrome, Lesch-Nyhan Syndrome, or the disinhibitory symptoms accompanying Post-traumatic Stress Disorder or dementia) in a primate with minimal sedative side effects by administering thereto a therapeutically effective amount of guanfacine. |
| Inventor(s): | Arnsten; Amy F. T. (Bethany, CT), Goldman-Rakic; Patricia S. (New Haven, CT), Hunt; Robert H. (Nashville, TN) |
| Assignee: | Arnsten; Amy F. T. (Bethany, CT) Goldman-Rakic; Patricia (New Haven, CT) Hunt; Robert H. (Nashville, TN) |
| Application Number: | 08/531,643 |
| Patent Claims: |
1. A method of treating a behavioral disinhibition in a primate without inducing excessive sedation, comprising
administering to the primate a behavior inhibiting dose of guanfacine, wherein the dose ranges between 0.01 mg/kg of body weight and 0.86 mg/kg of body weight. 2. The method of claim 1, comprising the additional step of readministering the dose at an interval required to obtain a desired level and duration of behavioral inhibition. 3. The method of claim 1, wherein the primate is a rhesus monkey. 4. The method of claim 1, wherein the primate is a human. 5. The method of claim 4, wherein the dose ranges between about 0.03 mg/kg of body weight and about 0.25 mg/kg of body weight. 6. The method of claim 1, wherein the behavioral disinhibition is one of Attention-Deficit Hyperactivity Disorder, Conduct Disorder, Oppositional-Defiant Disorder, Tourette's Syndrome, Lesch-Nyhan Syndrome, Post-Traumatic Stress Disorder and dementia. 7. A method of inhibiting a disinhibitory behavior in a primate without inducing excessive sedation, comprising: administering to the primate a behavior inhibiting dose of guanfacine, wherein the dose ranges between 0.01 mg/kg of body weight and 0.86 mg/kg of body weight. 8. The method of claim 7, comprising the additional step of readministering the dose at an interval required to obtain a desired level and duration of behavioral inhibition. 9. The method of claim 7, wherein the primate is a rhesus monkey. 10. The method of claim 7, wherein the primate is a human. 11. The method of claim 10, wherein the dose ranges between about 0.03 mg/kg of body weight and about 0.25 mg/kg of body weight. 12. The method of claim 7, wherein the behavior is one of hyperactivity, agitation, impulsivity, aggression, inattention, distractibility, disorganization, uncontrolled movements, and self-mutilation. |
